TERN
NASDAQ
US
Terns Pharmaceuticals, Inc. - Common Stock
$52.72
▼ $-0.07
(-0.13%)
Vol 10.9M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.3B
ROE
-30.0%
D/E
0.00
Beta
-0.26
52W
$2–$48
Wall Street Consensus
17 analysts · Apr 20265
Strong Buy
4
Buy
8
Hold
0
Sell
0
Strong Sell
52.9%
Buy Rating
Price Chart
Similar Stocks
AXSM
Axsome Therapeutics Inc
$9.2B
BLTE
Belite Bio Inc
$5.6B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
Earnings
Beat rate: 100.0%
Next Report
May 06, 2026
EPS Estimate: $-0.28
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.28 | — | — |
| Dec 2025 | $-0.28 | $-0.24 | +$0.04 |
| Sep 2025 | $-0.30 | $-0.27 | +$0.03 |
| Jun 2025 | $-0.30 | $-0.26 | +$0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -27.4% | -27.4% | -27.4% | -27.4% | -29.9% | -29.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 24.70 | 24.70 | 24.70 | 24.70 | 19.52 | 19.52 |
Key Ratios
ROA (TTM)
-28.5%
P/B
1.4
EPS (TTM)
$-1.03
CF/Share
$-1.27
52W High
$48.26
52W Low
$1.87
$1.87
52-Week Range
$48.26
How does TERN compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
TERN valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
—
▼
0%
below
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
1.4
▼
74%
below
peers
(5.2)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
TERN profitability vs Pharmaceuticals peers
ROE
-30.0%
▼
15%
below
peers
(-26.1%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-1.5%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(88.9%)
vs Peers
vs Industry
Top tier
ROA
-28.5%
▼
202%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
TERN financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
19.5
▲
461%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
-0.3
▼
144%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
TERN fundamentals radar
TERN
Peer median
Industry
TERN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
TERN vs peers: key metrics
Latest News
Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential
Yahoo Finance · Mar 29
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium”
Yahoo Finance · Mar 28
Terns Pharmaceuticals Stock Gains 5% Over Acquisition Deal With Merck
Nasdaq · Mar 25